- SMC recommends six products but rejects two for diabetes
- Lilly's Trulicity OK'd; can it top GLP-1 market?
- How AstraZeneca's revivified pipeline could boost Pfizer
- New CV data to add to alogliptin's safety allure?
COMMENT Other Informa Comment
- INTERVIEW: Novo CEO downplays Afrezza, pins hopes on oral pipeline
- Profile: GSK's Arturo Gonzalez on ethics, corruption and window cleaning